CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced they will be presenting additional linaclotide results from four pivotal Phase 3 trials and one Phase 2b study in patients with either irritable bowel syndrome with constipation (IBS-C) or chronic constipation (CC) at the American College of Gastroenterology (ACG) 2011 Annual Scientific Meeting being held in Washington, DC from October 29, 2011 to November 2, 2011. Linaclotide is an investigational guanylate cyclase type-C (GC-C) agonist for the treatment of IBS-C and CC. Positive results from each of these trials have been reported previously.
